STOK vs SRPT vs ALNY vs RARE

For growth investors, Stoke Therapeutics, Inc.

(STOK) is the stronger pick with 404. 5% revenue growth year-over-year, versus 15. 6% for Sarepta Therapeutics, Inc. (SRPT). Alnylam Pharmaceuticals, Inc. (ALNY) offers the better valuation at 127. 0x trailing P/E (39. 9x forward), making it the more compelling value choice. Analysts rate Stoke Therapeutics, Inc. (STOK) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Sarepta Therapeutics, Inc.

is actually cheaper at 5. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Alnylam Pharmaceuticals, Inc.

(ALNY) delivered a total return of +125. 4%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: ALNY returned +410. 4% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alnylam Pharmaceuticals, Inc.

(ALNY) is the lower-risk stock at 0. 74β versus Sarepta Therapeutics, Inc. 's 1. 95β — meaning SRPT is approximately 163% more volatile than ALNY relative to the S&P 500. On balance sheet safety, Sarepta Therapeutics, Inc. (SRPT) carries a lower debt/equity ratio of 91% versus 162% for Alnylam Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Stoke Therapeutics, Inc.

(STOK) is pulling ahead at 404. 5% versus 15. 6% for Sarepta Therapeutics, Inc. (SRPT). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, STOK leads at 145. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alnylam Pharmaceuticals, Inc.

(ALNY) is the more profitable company, earning 8. 4% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 8. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALNY leads at 13. 5% versus -79. 5% for RARE. At the gross margin level — before operating expenses — STOK leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sarepta Therapeutics, Inc.

(SRPT) trades at 5. 9x forward P/E versus 39. 9x for Alnylam Pharmaceuticals, Inc. — 34. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RARE: 85. 1% to $48. 36.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Alnylam Pharmaceuticals, Inc.

(ALNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 74), +410. 4% 10Y return). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALNY: +410. 4%, SRPT: +13. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.